Trial Profile
A phase 2 study of eribulin in combination with pertuzumab and trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms SONG-02
- 02 Oct 2019 Status changed from recruiting to discontinued.
- 10 Jul 2014 New trial record